The final decision on Novavax's COVID-19 vaccine approval by the US Food and Drug Administration has been delayed beyond the expected timeframe, causing uncertainty in the pharmaceutical and biotech sectors. The vaccine remains accessible through emergency use authorization obtained during the pandemic. Concerns have been raised over the delay in decision-making, potential impacts on Novavax's collaboration with Sanofi, and the influence of certain individuals on vaccine approvals. Despite the setback, Novavax remains optimistic about its vaccine's readiness for approval. The delay could affect its partnership with Sanofi and its place in the competitive vaccine market alongside Pfizer/BioNTech, Moderna, and Johnson & Johnson.